Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib (2014)
- Authors:
- Autor USP: HOFF, PAULO MARCELO GEHM - FM
- Unidade: FM
- DOI: 10.1007/s12032-014-0264-5
- Subjects: NEOPLASIAS HEPÁTICAS (TERAPIA); TAXA DE SOBREVIVÊNCIA; PROGNÓSTICO; ANTINEOPLÁSICOS
- Language: Inglês
- Imprenta:
- Source:
- Título: Medical Oncology
- ISSN: 1357-0560
- Volume/Número/Paginação/Ano: v. 31, art. 264, p. 1-6, 2014
- Status:
- Nenhuma versão em acesso aberto identificada
-
ABNT
FONSECA, Leonardo Gomes da et al. Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Medical Oncology, v. 31, p. 1-6, 2014Tradução . . Disponível em: https://doi.org/10.1007/s12032-014-0264-5. Acesso em: 06 maio 2026. -
APA
Fonseca, L. G. da, Barroso-Sousa, R., Bento, A. da S. A., Blanco, B. P., Valente, G. L., Pfiffer, T. E. F., et al. (2014). Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Medical Oncology, 31, 1-6. doi:10.1007/s12032-014-0264-5 -
NLM
Fonseca LG da, Barroso-Sousa R, Bento A da SA, Blanco BP, Valente GL, Pfiffer TEF, Hoff PM, Sabbaga J. Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib [Internet]. Medical Oncology. 2014 ; 31 1-6.[citado 2026 maio 06 ] Available from: https://doi.org/10.1007/s12032-014-0264-5 -
Vancouver
Fonseca LG da, Barroso-Sousa R, Bento A da SA, Blanco BP, Valente GL, Pfiffer TEF, Hoff PM, Sabbaga J. Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib [Internet]. Medical Oncology. 2014 ; 31 1-6.[citado 2026 maio 06 ] Available from: https://doi.org/10.1007/s12032-014-0264-5 - Should patients with advanced colorectal cancer and ECOG 3/4 be treated with chemotherapy?
- Primary prevention of colorectal cancer: Myth or reality?
- Drogas moleculares
- Perspectivas no cuidado dos tumores gastrointestinais
- Obesidade e câncer
- Combination of capecitabine and oxaliplatin is an effective treatment option for advanced neuroendocrine tumors
- Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer
- Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group
- Lack of association between ERCC1 expression in biliary tract malignancy and response to chemotherapy
- Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
